Bioinformatic and Functional Optimization of Antisense Phosphorodiamidate Morpholino Oligomers (PMOs) for Therapeutic Modulation of RNA Splicing in Muscle

Methods in Molecular Biology

Volumn 709, Issue , 2011, Pages 153-178

  Popplewell, Linda J ^a   Graham, Ian R ^a   Malerba, Alberto ^a   Dickson, George ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Antisense oligonucleotides; Bioinformatics; DMD; Exon skipping; Functional analysis; Optimization

Indexed keywords

COMPLEMENTARY DNA; DYSTROPHIN; MORPHOLINE DERIVATIVE; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER;

ALTERNATIVE RNA SPLICING; ARTICLE; BIOLOGY; DUCHENNE MUSCULAR DYSTROPHY; EXON; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE THERAPY; GENETICS; HUMAN; METABOLISM; METHODOLOGY; NUCLEOTIDE SEQUENCE; PHYSIOLOGY; RNA SPLICING; SKELETAL MUSCLE;

ALTERNATIVE SPLICING; COMPUTATIONAL BIOLOGY; DNA, ANTISENSE; DYSTROPHIN; EXONS; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE THERAPY; HUMANS; MORPHOLINES; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; READING FRAMES; RNA SPLICING;

EID: 79959981430     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61737-982-6_10     Document Type: Chapter

References (28)

1. Monaco AP, Bertelson CJ, Liechti-Gallati S, Moser H, Kunkel LM. (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2, 90–95.
2. Bertoni C. (2008) Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides. Front Biosci 13, 517–527.
3. Trollet C, Athanasopoulos T, Popplewell L, Malerba A, Dickson G. (2009) Gene therapy for muscular dystrophy: current progress and future prospects. Expert Opin Biol Ther 9, 849–866.
4. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, Den Dennen JT, Baas F, et al. (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12, 907–914.
5. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, et al. (2001) Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 10, 1547–1554.
6. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, et al. (2007) Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18, 798–810.
7. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, et al. (2003) Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 12, 907–914.
8. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT et al. (2004) Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 74, 83–92.
9. Aartsma-Rus A, Janson AA, van Ommen GJ, van Deutekom JCT. (2007) Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy. BMC Med Genet 8, 43–51.
10. Bremmer-Bout M, Aartsma-Rus A, de Meijer EJ, Kaman WE, Janson AA, Vossen RH, et al. (2004) Targeted exon skipping in transgenic hDMD mice: a model for direct preclinical screening of human-specific antisense oligonucleotides. Mol Ther 10, 232–240.
11. Graham IR, Hill VJ, Manoharan M, Inamati GB, Dickson G. (2004) Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. J Gene Med 6, 1149–1158.
12. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J, et al. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102, 198–203.
13. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, et al. (2001). Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 98, 42–47.
14. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S, et al. (2008) Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 16, 1624–1629.
15. van Deutekom JC, Janson AA, Ginjaar IB, Franzhuzen WS, Aartsma-Rus A, Bremmer-Bout M, et al. (2007) Local antisense dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 357, 2677–2687.
16. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, et al. (2009) Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8, 918–928.
17. Arora V, Devi GR, Iversen PL. (2004) Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol 5, 431–439.
18. Heemskerk HA, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ et al. (2009) In vivo comparison of 2′O-methyl-PS and morpholino antisense oligonucleotides for DMD exon skipping. J Gene Med 11, 257–266.
19. Gebski BL, Mann CJ, Fletcher S, Wilton SD. (2003) Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 12, 1801–1811.
20. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, et al. (2006) Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12, 175–177.
21. Malerba A, Thorogood FC, Dickson G, Graham IR. (2009) Dosing regimen has a significant impact on the ef ficiency of morpholino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 20, 955–965.
22. McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, et al. (2006) Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16, 583–590.
23. McClorey G, Moulton HM, Iversen PL, Fletcher S, Wilton SD. (2006) Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13, 1373–1381.
24. Aartsma-Rus A, Fokkema I, Verschuuren J, Ginjaar I, van Deutekom J, van Ommen GJ, et al. (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30, 292–299.
25. Aartsma-Rus A, De Winter CL, Janson AAM, Kaman WE, van Ommen G-JB, Den Dunnen JT, et al. (2005) Functional analysis of 114 exon-internal AONs for targeted DMD exon skipping: indication for steric hindrance of SR protein binding sites. Oligonucleotides 15, 284–297.
26. Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S. (2007) Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 15, 1288–1296.
27. Aartsma-Rus A, van Vliet L, Hirschi M, Janson AA, Heemskerk H, de Winter CL, et al. (2009) Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17, 548–553.
28. Popplewell LJ, Trollet C, Dickson G, Graham IR. (2009) Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther 17, 554–561.